Currently, individuals receiving augmentation therapy in the United States typically receive weekly infusions of Alpha1 Antitrypsin to raise their circulating levels. Typically the rule of thumb is that only severely deficient individuals receive therapy. Our work here and through the Mark Egly Foundation is making strides to change the standard of care so that others in need will receive treatment in the coming years!